<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Enhanced elimination of poisons
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Enhanced elimination of poisons
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Enhanced elimination of poisons
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael J Burns, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Larissa I Velez, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michele M Burns, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Ganetsky, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 08, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of the poisoned patient begins with a thorough evaluation, recognition that poisoning has occurred, identification of the agent(s) involved, assessment of severity, and prediction of toxicity. Therapy involves the provision of supportive care, prevention of poison absorption, and, when appropriate, the use of antidotes and other interventions to enhance elimination of the poison.
        </p>
        <p>
         Methods to enhance the rate of elimination of poisons following a toxic ingestion are reviewed here. General issues regarding the management of toxic ingestions, specific issues related to gastrointestinal decontamination and gastric emptying, and the diagnosis and management of specific poisonings are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         General poisoning (see
         <a class="medical medical_review" href="/z/d/html/324.html" rel="external">
          "General approach to drug poisoning in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13850.html" rel="external">
          "Initial management of the critically ill adult with an unknown overdose"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6496.html" rel="external">
          "Approach to the child with occult toxic exposure"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastrointestinal decontamination (see
         <a class="medical medical_review" href="/z/d/html/321.html" rel="external">
          "Gastrointestinal decontamination of the poisoned patient"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Select poisonings (see
         <a class="medical medical_review" href="/z/d/html/318.html" rel="external">
          "Acetaminophen (paracetamol) poisoning: Management in adults and children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/329.html" rel="external">
          "Salicylate (aspirin) poisoning: Clinical manifestations and evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/126052.html" rel="external">
          "Methanol and ethylene glycol poisoning: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/320.html" rel="external">
          "Lithium poisoning"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/332.html" rel="external">
          "Carbamazepine poisoning"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/338.html" rel="external">
          "Valproic acid poisoning"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/139762.html" rel="external">
          "Gabapentinoid poisoning and withdrawal"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/141081.html" rel="external">
          "GABA-B agonist (baclofen, phenibut) poisoning and withdrawal"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13844.html" rel="external">
          "Barbiturate (phenobarbital) poisoning"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1311445970">
         <span class="h1">
          GENERAL INDICATIONS AND CONTRAINDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Enhanced elimination techniques can accelerate removal of a toxin, but few studies have investigated whether they actually shorten the duration of clinical toxicity and/or improve clinical outcomes. The main methods of enhancing the elimination of toxins are listed in the table  (
         <a class="graphic graphic_table graphicRef57040" href="/z/d/graphic/57040.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         General indications for enhanced elimination techniques include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ingestion of a poison whose elimination can be enhanced.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Failure of a patient to respond to maximal supportive care.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The clinical course is predicted to be complicated based on the nature and/or concentration of the toxin, impaired clearance of the toxin, comorbid illness, concomitant severe electrolyte or other laboratory derangements that can be corrected with enhanced elimination, or some combination of these elements.
        </p>
        <p>
        </p>
        <p>
         In all cases, the expected benefits of the use of an enhanced elimination technique must be carefully weighed against the risk of potential complications associated with the technique.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          MULTIPLE-DOSE ACTIVATED CHARCOAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple-dose activated charcoal (MDAC) is a commonly used method for enhancing the elimination of toxins and may play an important role in specific poisonings. MDAC and other methods for gastrointestinal decontamination are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/321.html" rel="external">
          "Gastrointestinal decontamination of the poisoned patient", section on 'Multidose activated charcoal'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          URINARY ALKALINIZATION
         </span>
        </p>
        <p class="headingAnchor" id="H2859616494">
         <span class="h2">
          General concepts and mechanism
         </span>
         <span class="headingEndMark">
          —
         </span>
         The urinary excretion of some drugs can be enhanced by altering the urine pH [
         <a href="#rid1">
          1,2
         </a>
         ]. Altering the pH converts a lipid-soluble intact acid (HA) or base (BOH) in the tubular lumen into the charged salt (A- or B+):
        </p>
        <div class="formulaContainer">
         <div class="formula">
          <p>
           HA    &lt;—&gt;    H+   +   A-
          </p>
         </div>
        </div>
        <div class="formulaContainer">
         <div class="formula">
          <p>
           BOH    &lt;—&gt;    B+   +   OH-
          </p>
         </div>
        </div>
        <p>
         The charged particle is lipid-insoluble and cannot easily move back across the renal epithelium. This leads to a marked increase in drug excretion.
        </p>
        <p>
         Raising the urine pH to 7.5 to 8.0 in patients poisoned with weak acids (such as salicylates and
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         ) will drive the first reaction to the right, producing the desired increase in concentration of the charged salt (A-). Importantly, phenobarbital is the only barbiturate for which alkalinization is indicated, as short-acting barbiturates are metabolized in the liver, not eliminated via the kidney [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p>
         Urinary acidification (urine pH below 5.5) with ammonium chloride or ascorbic acid was used in the past to treat intoxications with weak bases such as amphetamines,
         <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">
          quinidine
         </a>
         , or phencyclidine. However, this practice has been abandoned, as efficacy has not been established and iatrogenic toxicity (from severe acidemia) can occur.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Indications and efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Drugs that are likely to respond to urinary alkalinization usually meet four criteria [
         <a href="#rid4">
          4,5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         They are predominantly eliminated unchanged by the kidney
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         They are distributed primarily in the extracellular fluid compartment
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         They are minimally protein-bound
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         They are weak acids with pKa ranging from 3.0 to 7.5
        </p>
        <p>
        </p>
        <p>
         Urinary alkalinization may be useful for helping to eliminate drugs listed in the following table  (
         <a class="graphic graphic_table graphicRef75710" href="/z/d/graphic/75710.html" rel="external">
          table 2
         </a>
         ). Diuresis with an isotonic fluid may enhance elimination of drugs listed here:  (
         <a class="graphic graphic_table graphicRef56838" href="/z/d/graphic/56838.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p>
         The clinical course of phenobarbital-poisoned patients may be improved by the use of urinary alkalinization [
         <a href="#rid2">
          2,6
         </a>
         ]. One study of 16 phenobarbital-poisoned patients found that the concomitant use of both urinary alkalinization and MDAC doubled the rate of elimination and shortened the period of unconsciousness by up to 50 percent compared with patients receiving supportive care alone [
         <a href="#rid2">
          2
         </a>
         ]. No comparable data exist showing improved clinical outcomes with the use of urinary alkalinization in other types of poisoning [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Urinary alkalinization is the most effective single method short of hemodialysis to enhance salicylate excretion, producing a mean elimination half-life of 5 hours versus half-lives of 8 and 19 hours in patients treated with isotonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         solution diuresis or standard supportive care, respectively [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/140354.html" rel="external">
          "Salicylate (aspirin) poisoning: Management", section on 'Serum and urine alkalinization'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Technique
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal of urinary alkalinization is to achieve a urine pH of 7.5 or higher while maintaining a serum pH no higher than 7.55 to 7.6. This is generally done by administering an intravenous (IV) bolus of 1 to 2 mEq/kg of 8.4 percent
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         , followed by continuous infusion of sodium bicarbonate. The fluid for continuous infusion is mixed by diluting 150 mEq of sodium bicarbonate into one liter of
         <a class="drug drug_general" data-topicid="8711" href="/z/d/drug information/8711.html" rel="external">
          5 percent dextrose in water
         </a>
         (D5W). Prior to the initiation of therapy, baseline measurements of electrolytes, blood urea nitrogen, serum creatinine, glucose, systemic pH, urinary pH, and serum drug concentrations should be performed. Placement of a Foley catheter is recommended to accurately measure urine output.
        </p>
        <p>
         Some hospitals have experienced shortages of
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         . In such cases,
         <a class="drug drug_general" data-topicid="9926" href="/z/d/drug information/9926.html" rel="external">
          sodium acetate
         </a>
         may be used as a substitute [
         <a href="#rid8">
          8
         </a>
         ]. Boluses of sodium acetate are potentially dangerous and should
         <strong>
          not
         </strong>
         be given. For use in poisoned patients, sodium acetate 1 mEq/kg body weight is administered IV over 15 to 20 minutes, followed by an infusion at twice the maintenance rate. As with sodium bicarbonate, the fluid for continuous infusion is mixed by diluting 150 mEq of sodium acetate into 1 liter of D5W. All other baseline laboratory measurements and precautions should be observed as above.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         After initial fluid resuscitation with isotonic 0.9%
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         or
         <a class="drug drug_general" data-topicid="108196" href="/z/d/drug information/108196.html" rel="external">
          Lactated Ringer
         </a>
         solution and intravenous bolus of
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         , the sodium bicarbonate continuous infusion should be administered at approximately 200 to 250 mL/hour. The rate should be titrated based on the urinary and systemic pH, which should be monitored throughout treatment. Intravenous fluid should be adjusted to maintain a urine pH ≥7.5 and serum pH &lt;7.60.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Children
         </span>
         <span class="headingEndMark">
          —
         </span>
         After initial fluid resuscitation with isotonic 0.9%
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         or
         <a class="drug drug_general" data-topicid="108196" href="/z/d/drug information/108196.html" rel="external">
          Lactated Ringer
         </a>
         solution and intravenous bolus of
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         , the sodium bicarbonate continuous infusion should be administered at approximately 1.5 times maintenance fluids. The rate should be titrated to maintain a urine pH ≥7.5. Increases in serum pH up to 7.60 are well tolerated in patients with normal renal function. Subsequent fluid administration should be based on urine output and ongoing losses. (See
         <a class="medical medical_review" href="/z/d/html/6122.html" rel="external">
          "Maintenance intravenous fluid therapy in children"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">
          Acetazolamide
         </a>
         should
         <strong>
          not
         </strong>
         be used to alkalinize the urine. Acetazolamide raises urine pH and lowers systemic pH, which may cause clinical deterioration in some cases. Close monitoring of blood and urine pH, electrolytes, respiratory status, and urine output is important when diuresis and urinary alkalinization procedures are performed. (See
         <a class="medical medical_review" href="/z/d/html/329.html" rel="external">
          "Salicylate (aspirin) poisoning: Clinical manifestations and evaluation", section on 'Pediatrics'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/140354.html" rel="external">
          "Salicylate (aspirin) poisoning: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Urine alkalinization is contraindicated in patients with established or incipient kidney failure, pulmonary edema, and cerebral edema. In addition, volume overload may complicate therapy in patients with preexisting cardiac disease [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complications of alkalinization include hypokalemia, excessive alkalemia, and ionized hypocalcemia, which results from increased protein binding of calcium. The administration of 20 to 40 meq/L (mmol/L)
         <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">
          potassium chloride
         </a>
         may be required if the plasma potassium concentration falls during urinary alkalinization. Monitoring and repletion of ionized calcium is recommended to prevent a deterioration in cardiac function.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          EXTRACORPOREAL REMOVAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Extracorporeal treatment (ECTR) of poisonings entails the use of a heterogenous group of modalities to promote removal of a toxicant and to support or temporarily replace the function of a vital organ. ECTR modalities include hemodialysis, hemoperfusion, hemofiltration, hemodiafiltration, therapeutic plasma exchange, exchange transfusion, and peritoneal dialysis. ECTR modalities are used in only 0.1 percent of poisonings [
         <a href="#rid9">
          9,10
         </a>
         ].
        </p>
        <p>
         Since 2012, expert and evidence-based consensus recommendations for ECTR for a number of poisons have been published by the Extracorporeal Treatments in Poisoning (EXTRIP) workgroup. This group of international experts principally recommend hemodialysis as the preferred ECTR for severe poisoning from long-acting barbiturates, ethylene glycol, methanol,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ,
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         , salicylate,
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         , thallium, and
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         ; and recommend against ECTR for poisoning from cyclic antidepressants, calcium channel blockers,
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">
          quinine
         </a>
         [
         <a href="#rid11">
          11-28
         </a>
         ]. Per this workgroup, ECTR is suggested for select cases of severe
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         , and
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         poisoning and may be reasonable for severe
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         toxicity [
         <a href="#rid15">
          15,21,23,25,29
         </a>
         ]. As of 2021, this workgroup has added recommendations for ECTR for patients with severe toxicity from gabapentinoids (eg,
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         ),
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">
          atenolol
         </a>
         , and
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         who also have concurrent kidney impairment [
         <a href="#rid30">
          30-32
         </a>
         ]. Details about ECTR and other aspects of management for these toxicants are found in the UpToDate topics devoted to the poisoning in question.
        </p>
        <p class="headingAnchor" id="H1939485460">
         <span class="h2">
          Hemodialysis and hemoperfusion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although rarely necessary for the care of poisoned patients, hemodialysis is used in greater than 95 percent of patients in whom extracorporeal treatment (ECTR) is employed to enhance poison elimination [
         <a href="#rid33">
          33-35
         </a>
         ]. During hemodialysis, up to 400 mL of blood per minute passes through an extracorporeal circuit in which toxic compounds in blood diffuse through a semipermeable membrane down a concentration gradient into a dialysate. Electrolyte disturbances and metabolic acidosis induced by certain drugs also can be readily corrected with this intervention. (See
         <a class="medical medical_review" href="/z/d/html/1852.html" rel="external">
          "Kidney replacement therapy (dialysis) in acute kidney injury: Metabolic and hemodynamic considerations"
         </a>
         .)
        </p>
        <p>
         Hemoperfusion refers to the circulation of blood through an extracorporeal circuit containing an adsorbent such as activated charcoal or polystyrene resin. In contrast to hemodialysis circuits, hemoperfusion devices contain thin, highly porous membranes and adsorbents that provide a large surface area to directly bind toxins [
         <a href="#rid36">
          36
         </a>
         ]. Clearance rates are higher with hemoperfusion than hemodialysis if the adsorbent binds the ingested toxin; the extraction ratio for hemoperfusion approximates 1.0 for some poisons, and drug clearance rates approach the rate of blood flow through the hemoperfusion circuit. The use of hemodialysis or hemoperfusion for the treatment of specific poisonings is discussed in the topics devoted to those toxins.
        </p>
        <p>
         Intermittent hemodialysis remains the first choice ECTR, rather than continuous renal replacement therapy (CRRT), due to its greater speed removing toxin in the early stages of treatment, when minimizing toxin exposure and distribution is critically important. In addition, hemodialysis is still more widely available worldwide and less costly than CRRT [
         <a href="#rid34">
          34,37,38
         </a>
         ]. The use of CRRT is discussed separately. (See
         <a class="local">
          'Continuous renal replacement therapy (hemofiltration)'
         </a>
         below.)
        </p>
        <p>
         Peritoneal dialysis is
         <strong>
          much less effective
         </strong>
         than hemodialysis or hemoperfusion, and is rarely, if ever, indicated in the care of poisoned patients.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hemodialysis is most useful in removing toxins with the following characteristics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low molecular weight (&lt;500 daltons)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Small volume of distribution (&lt;1 L/kg)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low degree of protein-binding
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High water solubility
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low endogenous clearance (&lt;4 mL/minute per kg)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High dialysis clearance relative to total body clearance.
        </p>
        <p>
        </p>
        <p>
         The utility of hemodialysis and hemoperfusion is limited when the drug is not concentrated in the extracellular fluid because of high lipid solubility and/or tight tissue binding. These characteristics are present with tricyclic antidepressants,
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         , and calcium channel blockers. (See
         <a class="medical medical_review" href="/z/d/html/295.html" rel="external">
          "Tricyclic antidepressant poisoning"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/319.html" rel="external">
          "Digitalis (cardiac glycoside) poisoning"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/331.html" rel="external">
          "Calcium channel blocker poisoning"
         </a>
         .)
        </p>
        <p>
         Hemodialysis removes the toxic metabolites of methanol and ethylene glycol, corrects acid-base abnormalities, and reduces end-organ sequelae and mortality associated with these poisonings [
         <a href="#rid36">
          36,39-41
         </a>
         ]. Although hemodialysis clears ethylene glycol and methanol efficiently, hemodialysis is not commonly indicated when acidosis is not present, as
         <a class="drug drug_general" data-topicid="8633" href="/z/d/drug information/8633.html" rel="external">
          fomepizole
         </a>
         effectively blocks the activation of these alcohols to the toxic acidic species [
         <a href="#rid42">
          42,43
         </a>
         ]. Treatment with hemodialysis early in the course of care may be prudent and cost effective for methanol-poisoned patients that present with high serum concentrations but no acidosis because endogenous clearance of methanol in those treated with fomepizole is slow. (See
         <a class="medical medical_review" href="/z/d/html/336.html" rel="external">
          "Methanol and ethylene glycol poisoning: Pharmacology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
         Hemodialysis substantially increases the rate of elimination of isopropanol, salicylates,
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         , and
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , although data regarding clinical end points are sparse [
         <a href="#rid36">
          36,44-47
         </a>
         ]. A 2015 systematic review supports the use of hemodialysis to remove
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         in cases of overdose [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/334.html" rel="external">
          "Isopropyl alcohol poisoning"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/329.html" rel="external">
          "Salicylate (aspirin) poisoning: Clinical manifestations and evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6501.html" rel="external">
          "Theophylline poisoning"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/320.html" rel="external">
          "Lithium poisoning"
         </a>
         .)
        </p>
        <p>
         Drugs adsorbed by activated charcoal can be extracted by hemoperfusion, and the rate of removal may exceed that achieved with hemodialysis. The extraction ratio of
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         with hemodialysis, for example, is approximately 50 percent as compared with 99 percent at the beginning of hemoperfusion (before the cartridge becomes saturated). As the extraction ratio only reflects the percent removal of drug presented to the dialysis membrane or hemoperfusion cartridge; these techniques remove only a small fraction of body load of drugs with large stores. (See
         <a class="medical medical_review" href="/z/d/html/6501.html" rel="external">
          "Theophylline poisoning"
         </a>
         .)
        </p>
        <p>
         High extraction ratios and clearance rates, however, do not necessarily predict improved clinical outcomes. No controlled clinical studies in poisoned patients have been performed to determine if hemoperfusion reduces morbidity or mortality as compared with supportive measures. Evidence of clinical effectiveness for hemoperfusion is based upon favorable pharmacokinetic data, animal studies, anecdotal case reports, case series, and uncontrolled retrospective studies. Three clinical studies have retrospectively compared hemoperfusion with supportive care for poisoning from a variety of drugs, but do not allow firm conclusions to be drawn regarding the relative efficacy of different management strategies [
         <a href="#rid48">
          48-50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         When intoxication has occurred with a drug whose hemodialysis clearance is significantly greater than endogenous clearance, the use of hemodialysis may be necessary if the patient's condition progressively deteriorates, or when measured drug concentrations are predictive of a poor outcome without hemodialysis [
         <a href="#rid36">
          36
         </a>
         ]. Practically, hemodialysis is indicated for a limited number of poisonings  (
         <a class="graphic graphic_table graphicRef82353" href="/z/d/graphic/82353.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
         Hemoperfusion may be considered for use in severe poisoning from the toxins listed in the following table  (
         <a class="graphic graphic_table graphicRef71695" href="/z/d/graphic/71695.html" rel="external">
          table 5
         </a>
         ). It is significantly more effective than hemodialysis in enhancing the clearance of
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         but is associated with a higher complication rate and is not available at most medical centers [
         <a href="#rid51">
          51
         </a>
         ]. If hemoperfusion is available, it is preferred over hemodialysis in these specific agents, but hemodialysis is an acceptable alternative.
        </p>
        <p class="headingAnchor" id="H4143667541">
         <span class="h3">
          Contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hemodialysis and hemoperfusion normally require systemic anticoagulation with heparin, and patients with active hemorrhage, severe thrombocytopenia, or coagulopathy may not be candidates for these procedures. However, when appropriate, hemodialysis can be performed without anticoagulation. Hemodialysis and hemoperfusion also may not be feasible in hypotensive patients. (See
         <a class="medical medical_review" href="/z/d/html/1840.html" rel="external">
          "Anticoagulation for the hemodialysis procedure"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1945.html" rel="external">
          "Intradialytic hypotension in an otherwise stable patient"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          Technique
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hemodialysis and hemoperfusion require central venous access with a double lumen catheter. Acute vascular access for hemodialysis or hemoperfusion is best accomplished with femoral catheters, which can be rapidly and safely inserted. Subclavian catheterization can also be used; however, there is a risk of pneumothorax or hemothorax, and therapy may be delayed because of the necessity for radiographic confirmation of proper catheter placement. The duration of these procedures for poisoned patients is usually four to eight hours but should be governed by the clinical response and serum drug concentrations. (See
         <a class="medical medical_review" href="/z/d/html/1843.html" rel="external">
          "Central venous catheters for acute and chronic hemodialysis access and their management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1938.html" rel="external">
          "Dialysis-related factors that may influence recovery of kidney function in acute kidney injury (acute renal failure)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2818064491">
         <span class="h3">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Potential side effects of hemodialysis include hypotension, bleeding due to anticoagulation, hypothermia, air embolus, and complications that may result from obtaining central venous access  (
         <a class="graphic graphic_table graphicRef77376" href="/z/d/graphic/77376.html" rel="external">
          table 6
         </a>
         ). Hemoperfusion has these same complications but also poses potential risks of charcoal embolization, hypocalcemia, hypoglycemia, leukopenia (10 percent reduction), and thrombocytopenia (30 percent reduction).
        </p>
        <p class="headingAnchor" id="H1811825013">
         <span class="h2">
          Continuous renal replacement therapy (hemofiltration)
         </span>
         <span class="headingEndMark">
          —
         </span>
         CRRT has gained acceptance as an alternative to hemodialysis and is commonplace in intensive care unit settings. CRRT includes four methods of continuous hemofiltration [
         <a href="#rid52">
          52
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Continuous veno-venous hemofiltration (CVVH)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Continuous veno-venous hemodiafiltration (CVVHD)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Continuous arterio-venous hemofiltration (CAVH)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Continuous arterio-venous hemodiafiltration (CAVHD)
        </p>
        <p>
        </p>
        <p>
         To perform CRRT, blood is pumped by the patient's own arterial (CAVH) or venous (CVVH) pressure, or by a hemodialysis machine entrained in the circuit (CAVHD, CVVHD). Blood that enters the hemofiltration circuit passes through filters (sheet membrane or hollow fiber) with large pores, and an ultrafiltrate forms, which drags solutes with molecular weights up to 50,000 daltons (depending upon hemofilter pore size). Cells and solutes larger than the pore size remain in the blood and return to the circulation.
        </p>
        <p>
         In contrast to hemodialysis or hemoperfusion, CAVH is driven by the patient's own blood pressure and so can be run continuously. The rate of fluid removal, which is equivalent to the plasma clearance of drug, can exceed 100 mL/hour; thus, fluid replacement is an essential component of the hemofiltration regimen. Hemofiltration is most often performed as CVVH or CVVHD, rather than CAVH or CAVHD.
        </p>
        <p>
         In general, CRRT has lower clearance rates than conventional hemodialysis. The advantages of CRRT are its applicability in hemodynamically unstable patients and its ability to be set up and delivered by regular intensive care unit staff [
         <a href="#rid37">
          37
         </a>
         ]. Data about drug removal using CRRT are limited [
         <a href="#rid53">
          53
         </a>
         ]. Hemofiltration has been used to enhance elimination of aminoglycosides,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         , and metal chelate complexes, but the technique does not remove highly protein-bound drugs effectively [
         <a href="#rid54">
          54
         </a>
         ]. It may also be of benefit for intoxications with drugs that have a large volume of distribution, tight tissue binding, or slow intercompartmental transfer (such as
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         ) [
         <a href="#rid37">
          37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1932.html" rel="external">
          "Drug removal in continuous kidney replacement therapy"
         </a>
         .)
        </p>
        <p>
         Complications of hemofiltration include clotting of the filter and bleeding due to the standard use of heparin (or citrate or alternative methods of anticoagulation). Fluid and electrolyte losses from the ultrafiltrate must be replaced continuously.
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          EXCHANGE TRANSFUSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Exchange transfusion refers to the removal of a quantity of blood from a poisoned patient and its replacement with an identical quantity of whole blood; the process is usually repeated two to three times. Exchange transfusions are rarely indicated but may be useful in the treatment of massive hemolysis (eg, due to arsine or sodium chlorate poisoning), severe methemoglobinemia, severe sulfhemoglobinemia (eg, secondary to hydrogen sulfide exposure), or neonatal drug toxicity. Complications of the technique include transfusion reactions, ionized hypocalcemia, and hypothermia [
         <a href="#rid55">
          55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7931.html" rel="external">
          "Massive blood transfusion"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2544007132">
         <span class="h1">
          ALTERNATIVE METHODS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other methods of poison treatment that function, in part, to enhance elimination of toxicants include: whole-bowel irrigation, plasmapheresis, cerebrospinal fluid removal, hyperbaric oxygen therapy, chelation therapy, specific antibody-toxin binding, enterohepatic circulatory binding of toxins, cation exchanger binding in the intestinal tract, and intravenous lipid emulsion therapy  (
         <a class="graphic graphic_table graphicRef57040" href="/z/d/graphic/57040.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h1">
          ADDITIONAL RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H1700279637">
         <span class="h2">
          Regional poison control centers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">
          "Society guideline links: Regional poison control centers"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2490273545">
         <span class="h2">
          Society guideline links
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">
          "Society guideline links: General measures for acute poisoning treatment"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/114014.html" rel="external">
          "Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General indications
         </strong>
         – The vast majority of patients who have ingested a poisonous substance or a toxic quantity of a drug can be managed with supportive measures. However, the severity of the ingestion and pharmacologic properties of the toxin may prompt consideration of techniques to enhance elimination of the poison in a small percentage of cases. Each technique is associated with potential complications, and the decision to use a particular technique should be based upon the drug ingested, the actual and predicted severity of poisoning, the presence of contraindications to the technique, and the effectiveness of alternative methods of treatment. (See
         <a class="local">
          'General indications and contraindications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multiple-dose activated charcoal (MDAC)
         </strong>
         – MDAC may be useful following specific ingestions and is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/321.html" rel="external">
          "Gastrointestinal decontamination of the poisoned patient", section on 'Multidose activated charcoal'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Urinary alkalinization
         </strong>
         – This may be useful for helping to eliminate drugs listed in the following table  (
         <a class="graphic graphic_table graphicRef75710" href="/z/d/graphic/75710.html" rel="external">
          table 2
         </a>
         ). These drugs are weak acids; the best studied are
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         and salicylates. This is generally done by administering an intravenous (IV) bolus of 1 to 2 mEq/kg of 8.4 percent
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         followed by a continuous infusion made by diluting 150 mEq of sodium bicarbonate into one liter of 5% dextrose in water. The goal is to achieve a urine pH &gt;7.5 and serum pH no higher than 7.55 to 7.6. (See
         <a class="local">
          'Urinary alkalinization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Isotonic fluid diuresis
         </strong>
         – This may enhance elimination of drugs that are predominantly eliminated unchanged by the kidney  (
         <a class="graphic graphic_table graphicRef56838" href="/z/d/graphic/56838.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Indications and efficacy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemodialysis
         </strong>
         – This may be useful for patients with significant ingestion of alcohols,
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , salicylates, and others presented in the table  (
         <a class="graphic graphic_table graphicRef82353" href="/z/d/graphic/82353.html" rel="external">
          table 4
         </a>
         ). Intermittent hemodialysis remains the first choice for extracorporeal removal compared with continuous renal replacement therapy due to its greater speed removing toxin in the early stages of treatment. (See
         <a class="local">
          'Hemodialysis and hemoperfusion'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemoperfusion
         </strong>
         –
         <strong>
         </strong>
         This extracorporeal removal modality refers to the circulation of blood through an extracorporeal circuit containing an adsorbent such as activated charcoal or polystyrene resin. It is not available at most medical centers, but compared with hemodialysis, may result in more rapid clearance of toxins such as
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         , and others presented in the table  (
         <a class="graphic graphic_table graphicRef71695" href="/z/d/graphic/71695.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="local">
          'Hemodialysis and hemoperfusion'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemofiltration
         </strong>
         – Continuous renal replacement therapy has lower clearance rates than conventional hemodialysis but may be used in the management of unstable patients. (See
         <a class="local">
          'Continuous renal replacement therapy (hemofiltration)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exchange transfusion
         </strong>
         – This refers to the removal of a quantity of blood from a poisoned patient and its replacement with an identical quantity of whole blood. It is rarely indicated but may be useful in the treatment of massive hemolysis (eg, due to arsine or sodium chlorate poisoning), severe methemoglobinemia, severe sulfhemoglobinemia (eg, secondary to hydrogen sulfide exposure), or neonatal drug toxicity. (See
         <a class="local">
          'Exchange transfusion'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Morgan AG, Polak A. The excretion of salicylate in salicylate poisoning. Clin Sci 1971; 41:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloomer HA. A critical evaluation of diuresis in the treatment of barbiturate intoxication. J Lab Clin Med 1966; 67:898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henry JA. Specific problems of drug intoxication. Br J Anaesth 1986; 58:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Proudfoot AT, Krenzelok EP, Vale JA. Position Paper on urine alkalinization. J Toxicol Clin Toxicol 2004; 42:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garrettson LK, Geller RJ. Acid and alkaline diuresis. When are they of value in the treatment of poisoning? Drug Saf 1990; 5:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frenia ML, Schauben JL, Wears RL, et al. Multiple-dose activated charcoal compared to urinary alkalinization for the enhancement of phenobarbital elimination. J Toxicol Clin Toxicol 1996; 34:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prescott LF, Balali-Mood M, Critchley JA, et al. Diuresis or urinary alkalinisation for salicylate poisoning? Br Med J (Clin Res Ed) 1982; 285:1383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neavyn MJ, Boyer EW, Bird SB, Babu KM. Sodium acetate as a replacement for sodium bicarbonate in medical toxicology: a review. J Med Toxicol 2013; 9:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gummin DD, Mowry JB, Spyker DA, et al. 2017 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 35th Annual Report. Clin Toxicol (Phila) 2018; 56:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jha VK, Padmaprakash KV. Extracorporeal Treatment in the Management of Acute Poisoning: What an Intensivist Should Know? Indian J Crit Care Med 2018; 22:862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calello DP, Liu KD, Wiegand TJ, et al. Extracorporeal Treatment for Metformin Poisoning: Systematic Review and Recommendations From the Extracorporeal Treatments in Poisoning Workgroup. Crit Care Med 2015; 43:1716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavergne V, Nolin TD, Hoffman RS, et al. The EXTRIP (EXtracorporeal TReatments In Poisoning) workgroup: guideline methodology. Clin Toxicol (Phila) 2012; 50:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghannoum M, Wiegand TJ, Liu KD, et al. Extracorporeal treatment for theophylline poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila) 2015; 53:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghannoum M, Laliberté M, Nolin TD, et al. Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila) 2015; 53:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anseeuw K, Mowry JB, Burdmann EA, et al. Extracorporeal Treatment in Phenytoin Poisoning: Systematic Review and Recommendations from the EXTRIP (Extracorporeal Treatments in Poisoning) Workgroup. Am J Kidney Dis 2016; 67:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mactier R, Laliberté M, Mardini J, et al. Extracorporeal treatment for barbiturate poisoning: recommendations from the EXTRIP Workgroup. Am J Kidney Dis 2014; 64:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghannoum M, Nolin TD, Goldfarb DS, et al. Extracorporeal treatment for thallium poisoning: recommendations from the EXTRIP Workgroup. Clin J Am Soc Nephrol 2012; 7:1682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yates C, Galvao T, Sowinski KM, et al. Extracorporeal treatment for tricyclic antidepressant poisoning: recommendations from the EXTRIP Workgroup. Semin Dial 2014; 27:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juurlink DN, Gosselin S, Kielstein JT, et al. Extracorporeal Treatment for Salicylate Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup. Ann Emerg Med 2015; 66:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Decker BS, Goldfarb DS, Dargan PI, et al. Extracorporeal Treatment for Lithium Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Clin J Am Soc Nephrol 2015; 10:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghannoum M, Yates C, Galvao TF, et al. Extracorporeal treatment for carbamazepine poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila) 2014; 52:993.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts DM, Yates C, Megarbane B, et al. Recommendations for the role of extracorporeal treatments in the management of acute methanol poisoning: a systematic review and consensus statement. Crit Care Med 2015; 43:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gosselin S, Juurlink DN, Kielstein JT, et al. Extracorporeal treatment for acetaminophen poisoning: recommendations from the EXTRIP workgroup. Clin Toxicol (Phila) 2014; 52:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mowry JB, Burdmann EA, Anseeuw K, et al. Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the EXTRIP Workgroup. Clin Toxicol (Phila) 2016; 54:103.
          </a>
         </li>
         <li class="breakAll">
          http://www.extrip-workgroup.org/recommendations.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong A, Hoffman RS, Walsh SJ, et al. Extracorporeal treatment for calcium channel blocker poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila) 2021; 59:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghannoum M, Roberts DM, Goldfarb DS, et al. Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Clin J Am Soc Nephrol 2022; 17:602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berling I, King JD, Shepherd G, et al. Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. J Am Soc Nephrol 2020; 31:2475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mowry JB, Shepherd G, Hoffman RS, et al. Extracorporeal treatments for isoniazid poisoning: Systematic review and recommendations from the EXTRIP workgroup. Pharmacotherapy 2021; 41:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouchard J, Shepherd G, Hoffman RS, et al. Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup. Crit Care 2021; 25:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghannoum M, Berling I, Lavergne V, et al. Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning. Kidney Int 2021; 100:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouchard J, Yates C, Calello DP, et al. Extracorporeal Treatment for Gabapentin and Pregabalin Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup. Am J Kidney Dis 2022; 79:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel N, Bayliss GP. Developments in extracorporeal therapy for the poisoned patient. Adv Drug Deliv Rev 2015; 90:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghannoum M, Roberts DM, Hoffman RS, et al. A stepwise approach for the management of poisoning with extracorporeal treatments. Semin Dial 2014; 27:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ouellet G, Bouchard J, Ghannoum M, Decker BS. Available extracorporeal treatments for poisoning: overview and limitations. Semin Dial 2014; 27:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garella S. Extracorporeal techniques in the treatment of exogenous intoxications. Kidney Int 1988; 33:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim Z, Goldfarb DS. Continuous renal replacement therapy does not have a clear role in the treatment of poisoning. Nephron Clin Pract 2010; 115:c1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouchard J, Lavergne V, Roberts DM, et al. Availability and cost of extracorporeal treatments for poisonings and other emergency indications: a worldwide survey. Nephrol Dial Transplant 2017; 32:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pappas SC, Silverman M. Treatment of methanol poisoning with ethanol and hemodialysis. Can Med Assoc J 1982; 126:1391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peterson CD, Collins AJ, Himes JM, et al. Ethylene glycol poisoning: pharmacokinetics during therapy with ethanol and hemodialysis. N Engl J Med 1981; 304:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonda A, Gault H, Churchill D, Hollomby D. Hemodialysis for methanol intoxication. Am J Med 1978; 64:749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brent J, McMartin K, Phillips S, et al. Fomepizole for the treatment of methanol poisoning. N Engl J Med 2001; 344:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brent J, McMartin K, Phillips S, et al. Fomepizole for the treatment of ethylene glycol poisoning. Methylpyrazole for Toxic Alcohols Study Group. N Engl J Med 1999; 340:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cutler RE, Forland SC, Hammond PG, Evans JR. Extracorporeal removal of drugs and poisons by hemodialysis and hemoperfusion. Annu Rev Pharmacol Toxicol 1987; 27:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansen HE, Amdisen A. Lithium intoxication. (Report of 23 cases and review of 100 cases from the literature). Q J Med 1978; 47:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosansky SJ. Isopropyl alcohol poisoning treated with hemodialysis: kinetics of isopropyl alcohol and acetone removal. J Toxicol Clin Toxicol 1982; 19:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winchester JF, Gelfand MC, Helliwell M, et al. Extracorporeal treatment of salicylate or acetaminophen poisoning--is there a role? Arch Intern Med 1981; 141:370.
          </a>
         </li>
         <li class="breakAll">
          Volans GN, Vale JA, Crome P, et al. The role of charcoal hemoperfusion in the management of acute poisoning by drugs. In: Artificial Organs, Kenedi RM, Bourtney JM, Gaylor JDS, Gilchris T (Eds), University Park Press, Baltimore 1976. p.178.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hampel G, Wiseman H, Widdop B. Acute poisoning due to hypnotics: the role of haemoperfusion in clinical perspective. Vet Hum Toxicol 1979; 21 Suppl:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bismuth C, Conso F, Wattel F, et al. Coated activated charcoal hemoperfusion: experience of French anti-poison centers about 60 cases. Vet Hum Toxicol 1979; 21 Suppl:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shannon MW. Comparative efficacy of hemodialysis and hemoperfusion in severe theophylline intoxication. Acad Emerg Med 1997; 4:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fertel BS, Nelson LS, Goldfarb DS. Extracorporeal removal techniques for the poisoned patient: a review for the intensivist. J Intensive Care Med 2010; 25:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mirrakhimov AE, Barbaryan A, Gray A, Ayach T. The Role of Renal Replacement Therapy in the Management of Pharmacologic Poisonings. Int J Nephrol 2016; 2016:3047329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Golper TA, Bennett WM. Drug removal by continuous arteriovenous haemofiltration. A review of the evidence in poisoned patients. Med Toxicol Adverse Drug Exp 1988; 3:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghannoum M, Gosselin S. Enhanced poison elimination in critical care. Adv Chronic Kidney Dis 2013; 20:94.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 325 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5123233" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The excretion of salicylate in salicylate poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5916138" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : A critical evaluation of diuresis in the treatment of barbiturate intoxication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3510648" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Specific problems of drug intoxication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15083932" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Position Paper on urine alkalinization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2190598" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Acid and alkaline diuresis. When are they of value in the treatment of poisoning?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8618250" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Multiple-dose activated charcoal compared to urinary alkalinization for the enhancement of phenobarbital elimination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6291695" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Diuresis or urinary alkalinisation for salicylate poisoning?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23636658" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Sodium acetate as a replacement for sodium bicarbonate in medical toxicology: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30576252" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : 2017 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 35th Annual Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30662226" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Extracorporeal Treatment in the Management of Acute Poisoning: What an Intensivist Should Know?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25860205" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Extracorporeal Treatment for Metformin Poisoning: Systematic Review and Recommendations From the Extracorporeal Treatments in Poisoning Workgroup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22578059" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The EXTRIP (EXtracorporeal TReatments In Poisoning) workgroup: guideline methodology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25715736" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Extracorporeal treatment for theophylline poisoning: systematic review and recommendations from the EXTRIP workgroup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25950372" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26578149" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Extracorporeal Treatment in Phenytoin Poisoning: Systematic Review and Recommendations from the EXTRIP (Extracorporeal Treatments in Poisoning) Workgroup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24998037" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Extracorporeal treatment for barbiturate poisoning: recommendations from the EXTRIP Workgroup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22837270" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Extracorporeal treatment for thallium poisoning: recommendations from the EXTRIP Workgroup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24712820" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Extracorporeal treatment for tricyclic antidepressant poisoning: recommendations from the EXTRIP Workgroup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25986310" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Extracorporeal Treatment for Salicylate Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25583292" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Extracorporeal Treatment for Lithium Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25355482" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Extracorporeal treatment for carbamazepine poisoning: systematic review and recommendations from the EXTRIP workgroup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25493973" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Recommendations for the role of extracorporeal treatments in the management of acute methanol poisoning: a systematic review and consensus statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25133498" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Extracorporeal treatment for acetaminophen poisoning: recommendations from the EXTRIP workgroup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26795743" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the EXTRIP Workgroup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26795743" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the EXTRIP Workgroup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33555964" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Extracorporeal treatment for calcium channel blocker poisoning: systematic review and recommendations from the EXTRIP workgroup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35236714" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32963091" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33660266" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Extracorporeal treatments for isoniazid poisoning: Systematic review and recommendations from the EXTRIP workgroup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34112223" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34358487" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34799138" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Extracorporeal Treatment for Gabapentin and Pregabalin Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26050528" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Developments in extracorporeal therapy for the poisoned patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24697864" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A stepwise approach for the management of poisoning with extracorporeal treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24697909" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Available extracorporeal treatments for poisoning: overview and limitations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3285069" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Extracorporeal techniques in the treatment of exogenous intoxications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20173343" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Continuous renal replacement therapy does not have a clear role in the treatment of poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28339843" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Availability and cost of extracorporeal treatments for poisonings and other emergency indications: a worldwide survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7083094" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Treatment of methanol poisoning with ethanol and hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7432434" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Ethylene glycol poisoning: pharmacokinetics during therapy with ethanol and hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/645740" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Hemodialysis for methanol intoxication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11172179" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Fomepizole for the treatment of methanol poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10080845" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Fomepizole for the treatment of ethylene glycol poisoning. Methylpyrazole for Toxic Alcohols Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3579241" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Extracorporeal removal of drugs and poisons by hemodialysis and hemoperfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/356084" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Lithium intoxication. (Report of 23 cases and review of 100 cases from the literature).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7131613" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Isopropyl alcohol poisoning treated with hemodialysis: kinetics of isopropyl alcohol and acetone removal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7008736" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Extracorporeal treatment of salicylate or acetaminophen poisoning--is there a role?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7008736" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Extracorporeal treatment of salicylate or acetaminophen poisoning--is there a role?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/505977" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Acute poisoning due to hypnotics: the role of haemoperfusion in clinical perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/505963" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Coated activated charcoal hemoperfusion: experience of French anti-poison centers about 60 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9223689" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Comparative efficacy of hemodialysis and hemoperfusion in severe theophylline intoxication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20444738" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Extracorporeal removal techniques for the poisoned patient: a review for the intensivist.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28042482" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : The Role of Renal Replacement Therapy in the Management of Pharmacologic Poisonings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3057325" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Drug removal by continuous arteriovenous haemofiltration. A review of the evidence in poisoned patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23265601" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Enhanced poison elimination in critical care.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
